|
gptkbp:instanceOf
|
gptkb:chemical_compound
|
|
gptkbp:ATCCode
|
gptkb:N02BA01
B01AC06
|
|
gptkbp:bioavailability
|
80-100%
|
|
gptkbp:CASNumber
|
50-78-2
|
|
gptkbp:contains
|
gptkb:WHO_Model_List_of_Essential_Medicines
|
|
gptkbp:contraindication
|
peptic ulcer
children with viral infections
hypersensitivity to NSAIDs
|
|
gptkbp:eliminationHalfLife
|
2-3 hours
|
|
gptkbp:hasFirstSynthesisBy
|
gptkb:Felix_Hoffmann
|
|
gptkbp:hasFirstSynthesisYear
|
1897
|
|
gptkbp:hasInChIKey
|
BSYNRYMUTXBXSQ-UHFFFAOYSA-N
|
|
gptkbp:hasLogP
|
1.19
|
|
gptkbp:hasMolecularFormula
|
C9H8O4
|
|
gptkbp:hasPatent
|
US644814A
|
|
gptkbp:hasPharmacologyAction
|
analgesic
anti-inflammatory
antipyretic
antiplatelet
|
|
gptkbp:hasSMILES
|
CC(=O)Oc1ccccc1C(=O)O
|
|
gptkbp:hasUNII
|
R16CO5Y76E
|
|
gptkbp:hasWikipediaPage
|
gptkb:Aspirin
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
CHEMBL98
|
|
gptkbp:indication
|
fever
pain
inflammation
prevention of cardiovascular events
|
|
gptkbp:isApprovedDrug
|
true
|
|
gptkbp:legalStatus
|
gptkb:OTC
|
|
gptkbp:marketedAs
|
gptkb:Bayer
|
|
gptkbp:mechanismOfAction
|
irreversible inhibition of cyclooxygenase (COX-1 and COX-2)
|
|
gptkbp:meltingPoint
|
135°C
|
|
gptkbp:metabolism
|
hepatic
|
|
gptkbp:molecularWeight
|
180.16
|
|
gptkbp:name
|
gptkb:Aspirin
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL98
2157
2244
D00109
DB00945
CHEBI:15365
|
|
gptkbp:routeOfAdministration
|
oral
intravenous
rectal
|
|
gptkbp:sideEffect
|
gptkb:Reye's_syndrome
gastrointestinal bleeding
allergic reaction
|
|
gptkbp:synonym
|
gptkb:2-Acetoxybenzoic_acid
gptkb:ASA
gptkb:Acetylsalicylic_acid
|
|
gptkbp:target
|
gptkb:PTGS2
gptkb:PTGS1
|
|
gptkbp:bfsParent
|
gptkb:lysergic_acid_diethylamide
|
|
gptkbp:bfsLayer
|
6
|